The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1737
September 15, 2025
View Complete Issue         Table of Contents 2019 
A New Heart Failure Indication for Finerenone (Kerendia)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A New Heart Failure Indication for Finerenone (Kerendia)
September 15, 2025 (Issue: 1737)
The FDA has approved the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Kerendia) to reduce the risk of cardiovascular death, hospitalization for heart failure (HF), and urgent HF visits in adults with HF with a left...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A New Heart Failure Indication for Finerenone (Kerendia)
Article code: 1737b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.